Unknown News
Unknown Market News
7d
Viatris Sees Analyst Upgrades, New Strategic Licensing, and Insider Moves in Recent Week
- Analysts raised their price targets on Viatris (VTRS), a new licensing deal emerged, and a key insider trade appeared—key developments for shareholders.
21d
Viatris Q2 2026 Results Showcase Pipeline Progress and Capital Returns
Viatris reported Q2 2026 revenues of $3.8B and raised full-year guidance, backed by FDA approval of Gwyn Lo patch and $550M returned to shareholders.
15 Aug at 01:05
Viatris Sells Biocon Biologics Stake for $815 Million, Reenters Biosimilars Market
Viatris sells Biocon Biologics stake for $815M, reenters biosimilars market.
02 Aug at 19:22
Viatris Stock Reaches New High Amid Strong Financial Performance
Viatris stock hits 52-week high of $17.68, driven by robust financial results.
26 Jul at 17:11
Viatris Stock Hits 52-Week High Amid Strong Financial Performance
Viatris stock reaches 52-week high following robust Q1 2026 results.
